03.31.25 -- Cell & Gene Therapy Manufacturing: Considerations For Early-Stage Companies

Learn how leveraging platform processes can enable flexible service at each level – pre-clinical through commercial – and reduce development timelines and costs on the path to market.

With experience in managing assay transfers across diverse sources and development stages, we have identified five critical factors that can significantly impact the success of potency assay transfers.

Discover how our integrated expertise in GLP toxicology, biodistribution, and CMC services helped a biotech company secure IND approval for a groundbreaking gene therapy.

Uncover the secrets behind successes in commercializing and producing commercial cell and gene therapies, including establishing standards of every day, manufacturing operational excellence.

To overcome manufacturing bottlenecks and reduce the high cost of gene therapies, our ATLAS platform has identified novel factors that boost rAAV9 production over 30-fold.

Help transform the development of advanced therapies by embracing a new standard that delivers quality, speed, and cost-efficiency without compromise.

Unlike traditional drugs, AAV therapies require extensive characterization and testing, demanding varying degrees of analysis at each stage of development.

Learn how three companies collaborated to develop a new antibiotic to address the increasing development of antimicrobial resistance (AMR) that threatens the global health landscape.

Review the benefits of a co-transcriptional capping RNA polymerase engineered to produce synthetic RNA to meet these increasing demands for safety and cost-effectiveness.